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Abstract 
Background and Aim: There are a limited number of studies regarding the clinicopathological features of gastric 
cancer. Here, the clinicopathological features of gastric cancer including tumor type and size, degree of differentiation, 
tumor operability, and immunohistochemically results of E-cadherin and P53 expression was investigated in Iranian 
patients. 
Methods: This retrospective study was performed on patients who were admitted at Imam Reza Hospital in Tehran-
Iran from 2008 to 2017 with a diagnosis of gastric cancer. Required information including age, sex, type of cancer, 
pathology, and immunohistochemistry (IHC) results and treatment were extracted from the hospital archive. 
Results: Out of 264 enrolled patients (with the mean age of 70.03±14.01 years), 180 cases were men. The frequency of 
intestinal-type, Diffuse-type, lymphoma and GIST tumor were 54.5%, 27.7%, 12.25% and 5.92% respectively. In 
addition, 67.58% and 13.83% of the tumors were undifferentiated and poorly differentiated respectively.  
Surgery was less probable in less differentiated tumors (r=0.582 P=0.001). The surgery rate in GIST, intestinal-type, 
and Diffuse-type tumors were 100%, 57%, and 14.4%, respectively. IHC results showed that E-cadherin expression was 
present in 78.6, of which 50.9% were weakly positive (+1). Also, the high expression of P53 was observed in 60.7% of 
patients.  
Conclusion: According to the data, we can conclude that poorly differentiated tumors, decreased expression of E-
cadherin, and increased expression of P53 is linked to poor prognosis in Iranian patients with gastric cancer. In this 
regard, further clinical trials and multicenter studies should be done to evaluate the possible factors for improving the 
prognosis and survival rates of Iranian patients with gastric cancer. 
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Introduction 
Gastric cancer is the 5th most common cancer, the 
third leading cause of cancer death worldwide (1), 
and the most common malignancy in Iranian men. 
The annual incidence of gastric cancer is 7300 in 
Iran and it is the first cause of Iranian cancer death 
in both sexes (2, 3). There are distinct histological 
subtypes of gastric cancer, which differ in their 
epidemiology, pathogenesis, genetic profile, and 
clinical outcomes (4, 5). In recent years, the 
discovery of different genes has increased our 
knowledge about the pathogenesis and clinical 
course of cancers. Different gene mutations can 
affect the prognosis as well as the treatment of 
choice. Gastric cancer has a variable distribution in 
the world, being the most common in Asian 
countries such as Japan and China, on the other 
hand, in Eastern Europe, gastric cancer incidence 
and mortality showed a continuous decline in the 
last decades, and this is more related to the 
intestinal type of gastric cancer rather than diffuse 
type (6, 7). In Iran, the highest incidence rate was 
observed in Ardabil, a northwestern province, with 
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an age-standardized incidence rate of 49.1 and 25.4 
in men and women respectively (8) However, 
gastric cancer is still the fourth most common 
malignancy worldwide and the second leading 
cause of cancer death (9). 
Numerous studies have evaluated the role of 
different genes such as p53 and E-cadherin and 
their expression or mutation in the development, 
severity, prognosis, and type of gastric cancer (10-
12). Studies show that the prevalence, prognosis, 
and genetic characteristics of gastric cancer vary by 
race and region (1, 13, 14). A study was revealed 
that nearly 50% of patients with diffuse gastric 
cancer had the mutation of E-cadherin (15). Also, 
different studies showed the effect of P53 
expression in patients with gastric cancer (16, 17). 
In this regard, because of the effect of P53 and E-
cadherin’s mutations on the progression and 
survival of patients with gastric cancer, the current 
study was designed. 
We know about the epidemiology of gastric cancer 
in Iran, but little is informed about its 
clinicopathological features. Therefore, in this 
study, we intend to examine these features, 
including tumor type and size, degree of 
differentiation, tumor operability, and 
immunohistochemical (IHC) reports on E. cadherin 
and P53 expression.  
Methods 
This retrospective study was performed on patients 
diagnosed with gastric cancer and who underwent 
biopsy or surgery during 2008-2017 in Imam Reza 
Hospital, Tehran, Iran. The inclusion criteria 
consisted of all patients older than 15 years old who 
had the pathology report of gastric cancer from 
2008 to 2017. However, the exclusion criteria 
implied patients who were referred to finalize their 
treatment or were lost to follow-up. The sample size 
of patients calculated by Cohen’s table should 
enroll at least 150 patients with P-Value <0.05. 
Informed consent was obtained from all individuals. 
The Ethics Committee at the Research Center 
approved the consent form and the protocol for 
Cancer Screening and Epidemiology, AJA 
University of Medical Sciences, Tehran, Iran 
(project code 91000321A).  
By referring to the hospital pathology ward and 
examining samples’ registries, all pathological 
reports of the patients in the mentioned period had 
been studied. The data collection form was 
completed based on the information in pathology 
reports, including patients’ age, sex, tumor location, 
sample size, final diagnosis and tumor size, and 
tumor grade; Meanwhile, a number of samples were 
deficient in the information that was corrected and 
completed by referring to patients’ admission 
records at the archives and phone calls to patients. 
Finally, 264 patients were enrolled in this study. 
Descriptive tests were applied for data presentation, 
also fisherman tests and Spearman correlation were 
done for comparisons. P-values less than 0.05 were 
considered statistically significant. SPSS version 24 
(Chicago, Illinois) was used for data analysis. 
Results 
There were 264 patients implied in this study (180 
men and 84 women). The age range of patients was 
15 to 118 years old with a mean age of 
70.03±14.01 years.  
Tissue samples were taken endoscopically in 169 
patients and surgically in 95 patients. These 
numbers include 35 studied cases that went under 
surgery after the endoscopic evaluation through the 
period of study.  
The diagnosis of gastric cancer was definite in 253 
patients. The pathology results are summarized in 
Table 1. The location of the sampling was 
determined in 185 cases. Samples were taken from 
the proximal gastric sections in 25 patients, the 
body in 12 cases, and distal sections in seven 
patients. Sampling was performed on multiple 
sections in 140 cases by either surgery or 
endoscopic evaluation. Sampling was performed 
only on gastric mucosa in 126 cases while it 
included other gastric levels as well in the rest of 
the cases.  
Among the 264 study cases, 253 (95.8%) were 
diagnosed with cancer, two were undetermined and 
9 patients did not have any malignancies in this 
regard. The type of tumor was determined in 177 
 Clinicopathological Characteristics of Gastric Cancer in Iranian Patients …                                      Sattartabar B, et al. 
Archives of Medical Laboratory Sciences; Volume 6, 2020 (Continuous Volume)  3 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
cases. Pathology results indicated that type of 
tumors in order of prevalence was as the following; 
intestinal, diffuse, lymphoma, and gastrointestinal 
tumor (GIST).  
Table 1: A summary of pathological findings  
Characteristics Pathology n (%) 
Cancer type 
Intestinal-type 138 (54.5%) 
Diffuse-type 69 (27.27%) 
Lymphoma 31 (12.25%) 
GIST 15 (5.92%) 
Degree of differentiation 
Well 4 (1.6%) 
Moderate 43 (17%) 
Poor 35 (13.83%) 
undifferentiated 171 (67.58%) 
Local lymph node metastasis 38.3% 
Tumor size 8.05±8.72cm 
 
Further histopathological evaluations of tumor 
grades indicated that in 1.6% of cases the tumor 
cells were well differentiated while 17.1% were 
moderately and 13.7% were poorly differentiated. 
No differentiation was observed in 67.7% of cases.  
In addition, 101 cases (38.3%) showed local lymph 
node metastasis. In the available results of tumor 
size in surgically treated patients (53 patients), 
results revealed that tumor volume was between 2 
to 45 square centimeters. However, the mean tumor 
size was 8.05 ± 8.72. Follow-ups indicated that 
among 264 studied patients, 109 cases (41.3%) had 
finally undergone surgical operations for tumor 
removal.As it shows, 54.5% of the tumors were 
intestinal-type and 67.58% of the tumors were 
undifferentiated. Spearman correlation showed that 
in men the tumor is larger (r=0.283 P=0.039) but 
more differentiated (r=0.373 P=0.006). Surgical 
resection was possible in 109 patients (41.3%). 
Spearman correlation showed that less 
differentiated tumors are less operable (r=0.582 
P=0.001). In addition, the type of tumor was also 
influential in the tumor operability, so that the rate 
of surgery in GIST, intestinal-type, and Diffuse-
type tumors were 100%, 57%, and 14.4%, 
respectively. The relationship between the 
possibility of surgery and other variables is 
summarized in Table 2. IHC results showed that E-
cadherin expression was present in 78.6%, of which 
50.9%% were weakly positive (+1) and 27.7% were 
strongly positive (+2). In addition, P53 high 
expression was observed in 60.7% of patients. 
There is no relationship between age, gender, tumor 
grade and size and IHC results. 
Table 2: IHC analysis of E-cadherin and P53 expression  
Characteristics IHC n(%) 
E-cadherin expression 
negative 48 (21.42%) 
Weakly positive (+1) 114 (50.89%) 
Strongly positive (+2) 62 (27.67%) 
P53 expression 
High 136 (60.7%) 
low 88 (39.3%) 
Discussion 
Gastric cancer is the 5th most common cancer, but 
it is the third leading cause of cancer death 
worldwide(1). Similar to the results of other 
countries, our study shows that in Iran, the majority 
of patients with gastric cancer are men (68.18% vs. 
31.82%). This is related to more smoking and 
alcohol consumption by men and the protective role 
of estrogen in women(18, 19).  
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The histologic type of cancer and its degree of 
differentiation are two important factors in 
predicting disease progression and patient survival. 
Also, increasing the depth of tumor invasion in the 
stomach wall is associated with a poor 
prognosis(20, 21). In our study, 67.58% of tumors 
were undifferentiated and 13.83% were poorly 
differentiated, indicating that gastric cancer is 
associated with poor prognosis in a large percentage 
of Iranian patients. In addition, local lymph node 
metastases were seen in 38.3% of patients, which 
further worsens the prognosis. Similar studies in 
other areas show that most gastric cancers are in the 
advanced stage at diagnosis and have a poor 
prognosis, with a five-year survival of less than 
25%(22, 23). 
Surgery is the primary treatment for resectable 
tumors and increases patients’ survival. patients 
with respectable localized tumors have the highest 
survival. In such cases, the surgical cure is possible 
in up to 90% of cases (24, 25). 
In our study, it was observed that most Iranian 
patients had undifferentiated or poorly 
differentiated tumors. In addition, in our study 
surgery was possible in only 109 patients (41.3%). 
Spearman correlation showed that surgery is less 
possible in poorly differentiated tumors (P =0.001 r 
=0.582). These results are consistent with the 
results of the study of Sun et al.(26). They showed 
that the rate of partial gastrectomy was 87.5% in 
well and moderately differentiated tumors and 25% 
in less differentiated tumors. In their study, all the 
well-differentiated cases were operable (partial or 
total gastrectomy) while less differentiated tumors 
were operable in only 62.5% and 37.5% of them 
were inoperable even after chemotherapy. In 
inoperable tumors, neoadjuvant chemotherapy can 
significantly increase the possibility of surgery (27-
29). 
In our study, the most common type of gastric 
cancer was intestinal-type followed by diffuse-type, 
which is similar to other regions (30, 31). Tumor 
type is another factor that affects the possibility of 
surgery. In our study, the surgery rate for GIST, 
intestinal-type, and diffuse-type tumors was 100%, 
57%, and 14.4%, respectively. It is known that 
Diffuse-type gastric cancers are undifferentiated 
tumors, highly Metastatic, less operable, and with 
poor prognosis(30). 
E-cadherin is a tumor suppressor and Loss of E-
cadherin expression can lead to dedifferentiation 
and invasion of cells(32). In our study, IHC results 
showed that EE-cadherin expression was negative 
in 21.4% and positive in 78.6% of cancers, which 
was weakly positive (+1) in 50.9% and strongly 
positive (+2) in only 27.7%. This indicates that in 
Iranian patients the E-cadherin expression has 
decreased in a large percentage of gastric cancers. 
In a meta-analysis, Xing et al.(22) Showed that E-
cadherin loss of expression is associated with 
decreased overall survival (HR = 1.87), higher 
TNM stage (OR = 2.52), lymph node metastasis 
(OR = 2.39), distant metastasis (OR = 2.23), and 
less differentiated tumors (OR=2.26). In addition, in 
their study, E-cadherin expression was significantly 
lower in patients with diffuse-type cancers 
compared to intestinal-type (OR = 4.22). 
Finally, p53 high expression is an independent 
predictor of shorter survival and tumor recurrence 
in gastric cancer (33, 34). In our study, most of the 
patients had P53 high expression (60.7) which was 
not related to gender, age, tumor size, and tumor 
grade. Sankalecha et al. (35) showed that P53 
expression was present in 90% of gastric cancers. In 
their study, 63.8% of patients showed P53 high 
expression and 36.2% of them showed P53 low 
expression and in contrast to our study, p53 high 
expression was associated with age, sex, tumor size, 
and tumor grade, but the data are somewhat 
conflicting, since in the study by Victorzon et al 
(36). P53 expression was not associated with 
gender, age, metastasis and it wasn’t an 
independent predictor of survival. It should be 
noted that due to the retrospective design of the 
study, the expression of E-cadherin and P53 were 
reported qualitatively, while the quantitative results 
provide more accurate information.  
Conclusion 
Most patients with gastric cancer are men and the 
most common type of gastric cancer in Iran is 
intestinal-type. The majority of Iranian patients 
have poorly differentiated or undifferentiated 
tumors, which reduces the possibility of surgery and 
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survival. In addition, a large number of patients had 
decreased E-cadherin expression and increased P53 
expression, both of which are associated with poor 
prognosis. 
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